Janux Retained Earnings from 2010 to 2024

JANX Stock

USD 45.21 1.18 2.54%

Janux Therapeutics Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that Janux Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2010-12-31

Previous Quarter

-168.8 M

Current Value

-160.3 M

Quarterly Volatility

57.9 M

Credit Downgrade

Yuan Drop

Covid

Check Janux Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Janux Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 13.1 M, Depreciation And Amortization of 2.1 M or Interest Expense of 4.9 M, as well as many indicators such as Price To Sales Ratio of 55.51, Dividend Yield of 0.0 or PTB Ratio of 1.44. Janux financial statements analysis is a perfect complement when working with Janux Therapeutics Valuation or Volatility modules.

Check out the analysis of Janux Therapeutics Correlation against competitors.

For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.

Latest Janux Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Janux Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Janux Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Janux Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (168.76 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Janux Retained Earnings Regression Statistics

	Arithmetic Mean	(38,750,523)
	Coefficient Of Variation	(149.46)
	Mean Deviation	44,262,234
	Median	(7,955,000)
	Standard Deviation	57,917,703
	Sample Variance	3354.5T
	Range	160.8M
	R-Value	(0.75)
	Mean Square Error	1576.7T
	R-Squared	0.56
	Significance	0
	Slope	(9,722,100)
	Total Sum of Squares	46962.4T

Janux Retained Earnings History

	2024	-160.3 M
	2023	-168.8 M
	2022	-110.5 M
	2021	-47.4 M
	2020	-14.7 M

Other Fundumenentals of Janux Therapeutics

Retained Earnings Total Equity

Janux Therapeutics Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Capital Surpluse
Total Assets		1.0	0.97	-0.63	-0.84	1.0	0.74	1.0	-0.48	1.0	1.0	1.0	-0.81	1.0	0.83	0.73	0.68
Total Stockholder Equity	1.0		0.97	-0.64	-0.83	1.0	0.7	1.0	-0.47	1.0	1.0	1.0	-0.79	1.0	0.81	0.74	0.67
Net Tangible Assets	0.97	0.97		-0.52	-0.9	0.97	0.72	0.97	-0.66	0.97	0.97	0.97	-0.8	0.97	0.89	0.67	0.74
Net Debt	-0.63	-0.64	-0.52		0.16	-0.62	-0.38	-0.63	-0.22	-0.65	-0.59	-0.65	0.66	-0.59	-0.19	-0.92	0.12
Retained Earnings	-0.84	-0.83	-0.9	0.16		-0.84	-0.81	-0.83	0.82	-0.83	-0.86	-0.83	0.67	-0.86	-0.99	-0.37	-0.93
Accounts Payable	1.0	1.0	0.97	-0.62	-0.84		0.73	1.0	-0.5	1.0	1.0	1.0	-0.82	1.0	0.82	0.72	0.69
Total Liab	0.74	0.7	0.72	-0.38	-0.81	0.73		0.7	-0.48	0.72	0.75	0.72	-0.78	0.75	0.84	0.46	0.69
Net Invested Capital	1.0	1.0	0.97	-0.63	-0.83	1.0	0.7		-0.47	1.0	1.0	1.0	-0.79	1.0	0.81	0.74	0.67
Short Long Term Debt	-0.48	-0.47	-0.66	-0.22	0.82	-0.5	-0.48	-0.47		-0.47	-0.5	-0.48	0.44	-0.5	-0.79	-0.01	-0.81
Total Current Assets	1.0	1.0	0.97	-0.65	-0.83	1.0	0.72	1.0	-0.47		1.0	1.0	-0.81	1.0	0.81	0.74	0.66
Capital Stock	1.0	1.0	0.97	-0.59	-0.86	1.0	0.75	1.0	-0.5	1.0		1.0	-0.78	1.0	0.85	0.7	0.71
Net Working Capital	1.0	1.0	0.97	-0.65	-0.83	1.0	0.72	1.0	-0.48	1.0	1.0		-0.82	1.0	0.81	0.74	0.66
Short Term Debt	-0.81	-0.79	-0.8	0.66	0.67	-0.82	-0.78	-0.79	0.44	-0.81	-0.78	-0.82		-0.78	-0.64	-0.62	-0.49
Common Stock	1.0	1.0	0.97	-0.59	-0.86	1.0	0.75	1.0	-0.5	1.0	1.0	1.0	-0.78		0.85	0.7	0.71
Property Plant Equipment	0.83	0.81	0.89	-0.19	-0.99	0.82	0.84	0.81	-0.79	0.81	0.85	0.81	-0.64	0.85		0.42	0.89
Current Deferred Revenue	0.73	0.74	0.67	-0.92	-0.37	0.72	0.46	0.74	-0.01	0.74	0.7	0.74	-0.62	0.7	0.42		0.04
Capital Surpluse	0.68	0.67	0.74	0.12	-0.93	0.69	0.69	0.67	-0.81	0.66	0.71	0.66	-0.49	0.71	0.89	0.04

Click cells to compare fundamentals

About Janux Therapeutics Financial Statements

Janux Therapeutics investors use historical fundamental indicators, such as Janux Therapeutics' Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Janux Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	-168.8 M	-160.3 M
Retained Earnings Total Equity	-99.4 M	-104.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC